A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowany nieoperacyjny, zaawansowany rak nerki potwierdzony badaniem histologicznym.
- •Rak nerki w stadium IV.
- •Choroba jest widoczna w badaniach obrazowych.
- •Pacjent otrzymał maksymalnie 3 wcześniejsze metody leczenia systemowego raka nerki, w tym tylko 1 terapię anty-PD-1/PD-L1.
✗ Disqualifies
- •Poziom tlenu we krwi poniżej 92% w spoczynku, potrzeba tlenu dodatkowego lub stałego.
- •Znaczące choroby serca w ciągu ostatniego roku.
- •Zakrzepica żył głębokich w ciągu ostatnich 3 miesięcy (chyba że jest stabilna, bez objawów i leczona antykoagulantami od 4 tygodni).
- •Osłabiona funkcja lewej komory serca (poniżej 50%).
- •Duża operacja w ciągu ostatnich 8 tygodni.
- •Aktywne zapalenie płuc lub choroby śródmiąższowej płuc.
- •Zakażenie wirusem HIV, wirusem zapalenia wątroby typu B lub C.
- •Inny czynny nowotwór złośliwy w ciągu ostatnich 3 lat.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (59)
Centro Oncologico Korben ( Site 0254)
CABA, Argentina
Hospital Italiano de Buenos Aires ( Site 0253)
Ciudad de Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
Mar del Plata, Argentina
Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
Río Cuarto, Argentina
Sanatorio Parque ( Site 0251)
Rosario, Argentina
Instituto de Oncología de Rosario ( Site 0257)
Rosario, Argentina
Instituto Alexander Fleming ( Site 0252)
CABA, Argentina
Centro Oncológico Riojano Integral ( Site 0256)
La Rioja, Argentina
COE (Centro Oncológico de Excelencia) ( Site 0259)
San Juan, Argentina
Macquarie University ( Site 2700)
Macquarie University, Australia
Instituto do Câncer e Transplante de Curitiba ( Site 0300)
Curitiba, Brazil
Masarykuv onkologicky ustav ( Site 0903)
Brno, Czechia
Fakultni nemocnice Ostrava ( Site 0904)
Ostrava, Czechia
Fakultni nemocnice Hradec Kralove ( Site 0902)
Hradec Králové, Czechia
Fakultni nemocnice v Motole ( Site 0900)
Prague, Czechia
Herlev Hospital ( Site 1002)
Herlev, Denmark
Aarhus Universitetshospital, Skejby ( Site 1001)
Aarhus, Denmark
Centre Antoine Lacassagne ( Site 1209)
Nice, France
Hopital Europeen Marseille ( Site 1216)
Marseille, France
LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
Toulouse, France
CHU Angers ( Site 1204)
Angers, France
Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
Le Mans, France
CHU de Saint-Etienne ( Site 1202)
Saint Priest En Jarez, France
Universitätsklinikum Jena ( Site 1313)
Jena, Germany
Alexandra General Hospital of Athens ( Site 1400)
Athens, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
Athens, Greece
Metropolitan Hospital ( Site 1402)
Athens, Greece
Rambam Health Care Campus ( Site 1600)
Haifa, Israel
Meir Medical Center. ( Site 1603)
Kfar Saba, Israel
Rabin Medical Center ( Site 1602)
Petah Tikva, Israel
Sheba Medical Center ( Site 1601)
Ramat Gan, Israel
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
Meldola, Italy
Azienda Ospedaliera Universitaria Careggi ( Site 1807)
Florence, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
Milan, Italy
AO Santa Maria della Misericordia ( Site 1805)
Perugia, Italy
Istituto Nazionale Tumori Regina Elena ( Site 1804)
Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
Roma, Italy
Maastricht UMC+ ( Site 1901)
Maastricht, Netherlands
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
Amsterdam, Netherlands
Haga Ziekenhuis locatie Leyweg ( Site 1906)
The Hague, Netherlands
AIDPORT Sp. z o.o. ( Site 2118)
Skórzewo, Poland
Pratia MCM Krakow ( Site 2115)
Krakow, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2102)
Siedlce, Poland
MTZ Clinical Research Powered by Pratia ( Site 2107)
Warsaw, Poland
Severance Hospital, Yonsei University Health System ( Site 2903)
Seoul, South Korea
Asan Medical Center ( Site 2901)
Seoul, South Korea
Samsung Medical Center ( Site 2902)
Seoul, South Korea
Hospital Universitario Virgen del Rocio ( Site 2306)
Seville, Spain
Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
L'Hospitalet de Llobregat, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
Madrid, Spain
Hospital Universitari Vall d'Hebron ( Site 2303)
Barcelona, Spain
Hospital Insular de Gran Canaria ( Site 2308)
Las Palmas, Spain
Hospital Universitario 12 de Octubre ( Site 2300)
Madrid, Spain
Fundación Instituto Valenciano de Oncología ( Site 2307)
Valencia, Spain
Hacettepe Universite Hastaneleri ( Site 2500)
Sıhhiye, Turkey (Türkiye)
Adana Medical Park Seyhan Hastanesi ( Site 2505)
Adana, Turkey (Türkiye)
Trakya University Medical Faculty Hospital ( Site 2502)
Edirne, Turkey (Türkiye)
Koc Universitesi Hastanesi ( Site 2501)
Istanbul, Turkey (Türkiye)
The Christie Hospital NHS Foundation Trust ( Site 2601)
Withington, United Kingdom
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.